Profile data is unavailable for this security.
About the company
Genelux Corporation is a late clinical-stage biopharmaceutical company. The Company is focused on developing a pipeline of next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its clinical and preclinical product candidates are intended to selectively kill tumor cells and induce a robust immune response against a patient’s tumor neoantigens. Its product candidate, Olvi-Vec (olvimulogene nanivacirepvec), is a proprietary, modified strain of the vaccinia virus (VACV), a stable deoxyribonucleic acid (DNA) virus with a large engineering capacity. Olvi-Vec is developed for the treatment of multiple cancers based on the results of preclinical studies that suggest Olvi-Vec has the potential to infect and directly kill a wide range of tumor cell types in vitro and in vivo and produce an anti-tumor immune response. Its portfolio also include oncolytic vaccinia immunotherapy clinical candidates.
- Revenue in USD (TTM)8.00k
- Net income in USD-27.66m
- Incorporated2001
- Employees23.00
- LocationGenelux Corp2625 Townsgate Road, Suite 230WESTLAKE VILLAGE 91361United StatesUSA
- Phone+1 (805) 267-9889
- Fax+1 (302) 636-5454
- Websitehttps://genelux.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Werewolf Therapeutics Inc | 3.39m | -62.12m | 79.32m | 45.00 | -- | 0.8707 | -- | 23.43 | -1.50 | -1.50 | 0.0819 | 2.04 | 0.0214 | -- | 1.06 | 72,042.55 | -39.26 | -- | -42.91 | -- | -- | -- | -1,834.55 | -- | -- | -- | 0.2228 | -- | 21.60 | -- | 30.56 | -- | -- | -- |
| Renovaro Inc | 0.00 | -115.69m | 79.49m | 25.00 | -- | 0.8047 | -- | -- | -0.9343 | -0.9343 | 0.00 | 0.6223 | 0.00 | -- | -- | 0.00 | -128.97 | -39.86 | -158.19 | -42.11 | -- | -- | -- | -- | -- | -9.65 | 0.0259 | -- | -- | -- | -103.23 | -- | -37.12 | -- |
| PDS Biotechnology Corp | 0.00 | -40.56m | 81.00m | 25.00 | -- | 3.68 | -- | -- | -1.17 | -1.17 | 0.00 | 0.5975 | 0.00 | -- | -- | 0.00 | -73.98 | -51.63 | -98.74 | -59.00 | -- | -- | -- | -- | -- | -19.13 | 0.5286 | -- | -- | -- | -5.11 | -- | -- | -- |
| Allakos Inc | 0.00 | -178.75m | 81.03m | 131.00 | -- | 1.11 | -- | -- | -2.03 | -2.03 | 0.00 | 0.8142 | 0.00 | -- | -- | 0.00 | -87.64 | -42.71 | -97.01 | -45.11 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 41.96 | -- | -38.89 | -- |
| Chimerix Inc | 159.00k | -83.59m | 82.17m | 72.00 | -- | 0.6052 | -- | 516.82 | -0.9351 | -0.9351 | 0.0018 | 1.51 | 0.0008 | -- | 1.92 | 2,208.33 | -43.54 | -30.45 | -48.29 | -34.09 | 2.52 | -- | -52,574.84 | -442.93 | -- | -- | 0.00 | -- | -99.04 | -46.24 | -147.68 | -- | -13.24 | -- |
| Relmada Therapeutics Inc | 0.00 | -86.49m | 82.98m | 20.00 | -- | 1.74 | -- | -- | -2.87 | -2.87 | 0.00 | 1.58 | 0.00 | -- | -- | 0.00 | -104.91 | -- | -116.60 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 37.09 | -- | -- | -- |
| PMV Pharmaceuticals Inc | 0.00 | -51.47m | 83.31m | 63.00 | -- | 0.421 | -- | -- | -0.9998 | -0.9998 | 0.00 | 3.82 | 0.00 | -- | -- | 0.00 | -21.24 | -21.16 | -22.36 | -21.91 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 5.94 | -- | 16.31 | -- |
| Fibrobiologics Inc | 0.00 | -17.78m | 83.53m | 10.00 | -- | 29.87 | -- | -- | -0.8864 | -0.8864 | 0.00 | 0.0807 | 0.00 | -- | -- | 0.00 | -149.60 | -- | -225.38 | -- | -- | -- | -- | -- | -- | -- | 0.0403 | -- | -- | -- | -272.15 | -- | -- | -- |
| Invivyd Inc | 11.56m | -225.14m | 83.59m | 94.00 | -- | 1.01 | -- | 7.23 | -1.95 | -1.95 | 0.0996 | 0.6953 | 0.0529 | -- | 2.48 | 123,021.30 | -103.08 | -- | -135.83 | -- | 92.27 | -- | -1,946.87 | -- | 1.58 | -- | 0.00 | -- | -- | -- | 17.68 | -- | -- | -- |
| MDxHealth SA | 80.74m | -40.80m | 84.64m | 300.00 | -- | -- | -- | 1.05 | -1.54 | -1.54 | 3.06 | -0.3229 | 0.5906 | 9.39 | 7.49 | 269,136.70 | -29.85 | -51.62 | -43.63 | -64.72 | 62.64 | 50.88 | -50.54 | -117.64 | 0.8252 | -1.74 | 1.18 | -- | 89.43 | 19.84 | 2.14 | -- | 30.13 | -- |
| Genelux Corp | 8.00k | -27.66m | 84.96m | 23.00 | -- | 2.54 | -- | 10,619.66 | -0.9537 | -0.9537 | 0.0003 | 0.9703 | 0.0002 | -- | -- | 347.83 | -74.41 | -- | -92.15 | -- | -- | -- | -345,750.00 | -- | -- | -- | 0.00 | -- | -98.46 | -- | -443.44 | -- | -- | -- |
| Generation Bio Co | 18.58m | -145.47m | 88.17m | 174.00 | -- | 0.8437 | -- | 4.74 | -2.19 | -2.19 | 0.2797 | 1.56 | 0.059 | -- | 56.31 | 106,793.10 | -46.16 | -36.96 | -51.29 | -39.21 | -- | -- | -782.87 | -8,879.44 | -- | -- | 0.00 | -- | -- | 177.31 | 7.34 | -- | 19.61 | -- |
| Inotiv Inc | 501.06m | -99.22m | 88.69m | 1.96k | -- | 0.487 | -- | 0.177 | -3.84 | -3.84 | 19.44 | 7.00 | 0.615 | 8.12 | 6.83 | 256,297.70 | -12.11 | -23.84 | -19.28 | -29.26 | 24.93 | 29.31 | -19.70 | -33.24 | 0.2279 | -0.6234 | 0.6774 | -- | 4.52 | 85.10 | 68.80 | -- | 83.64 | -- |
| Quince Therapeutics Inc | 0.00 | -53.26m | 90.02m | 32.00 | -- | 2.00 | -- | -- | -1.25 | -1.25 | 0.00 | 1.04 | 0.00 | -- | -- | 0.00 | -50.27 | -42.72 | -52.16 | -46.06 | -- | -- | -- | -- | -- | -- | 0.249 | -- | -- | -- | 39.25 | -- | -5.47 | -- |
| Hillevax Inc | 0.00 | -150.28m | 90.65m | 90.00 | -- | 0.4886 | -- | -- | -3.09 | -3.09 | 0.00 | 3.73 | 0.00 | -- | -- | 0.00 | -51.15 | -- | -54.17 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 22.68 | -- | -- | -- |
Data as of Nov 22 2024. Currency figures normalised to Genelux Corp's reporting currency: US Dollar USD
11.61%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Woodward Diversified Capital LLCas of 30 Sep 2024 | 1.34m | 3.89% |
| The Vanguard Group, Inc.as of 30 Sep 2024 | 977.42k | 2.83% |
| Millennium Management LLCas of 30 Sep 2024 | 364.93k | 1.06% |
| Geode Capital Management LLCas of 30 Sep 2024 | 316.16k | 0.92% |
| BlackRock Fund Advisorsas of 30 Sep 2024 | 305.33k | 0.88% |
| Bank of America, NA (Private Banking)as of 30 Sep 2024 | 216.78k | 0.63% |
| Provident Wealth Management LLCas of 30 Sep 2024 | 158.87k | 0.46% |
| Renaissance Technologies LLCas of 30 Sep 2024 | 122.54k | 0.36% |
| Marshall Wace LLPas of 30 Sep 2024 | 103.10k | 0.30% |
| Affinity Asset Advisors LLCas of 30 Sep 2024 | 100.00k | 0.29% |
More ▼
Data from 30 Sep 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
